An Open-Label Split-Body Clinical Trial Evaluating Therapeutic Efficacy and Safety of Cold Atmospheric Plasma in Canine Acute Otitis Externa.

CAP demonstrates efficacy and safety comparable to standard topical therapy for canine acute otitis externa.

This open-label split-body clinical trial evaluated cold atmospheric plasma (CAP) as a novel therapeutic approach for canine acute otitis externa. Twenty-two dogs with bilateral acute otitis externa were enrolled in two treatment groups with different CAP application schedules. Group 1 received CAP on days 0 and 5, while Group 2 received CAP on days 0, 3, 6, and 9. Both groups had one ear treated with standard topical antimicrobial/antifungal/corticosteroid therapy for 10 days as control. Assessment parameters included the Otitis Index Score (OTIS-3) and cytological evaluation at multiple timepoints (days 0, 5, 10, and 15). Results demonstrated significant reductions in both OTIS-3 and cytological scores over time in CAP-treated ears, comparable to standard treatment. Investigators and owners rated treatment response as good-to-excellent in nearly all CAP cases. The treatment demonstrated excellent tolerability with no reported adverse effects. These findings suggest CAP warrants further investigation as a promising adjunctive or alternative therapy for managing acute canine otitis externa.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.